C07D 295/30
Non-acylated
Official title: non-acylated
C07D295/30 (Non-acylated) appears on 134 US grants and 100 published applications in this corpus.
Search patents in C07D- Granted patents
- 134
- Published applications
- 100
- Assignees
- 96
- Inventors
- 357
- Latest grant
- 10 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 4 | 0 |
| 1980 | 2 | 0 |
| 1981 | 3 | 0 |
| 1982 | 2 | 0 |
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 4 | 0 |
| 1996 | 4 | 0 |
| 1997 | 1 | 0 |
| 1998 | 4 | 0 |
| 1999 | 4 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 0 |
| 2002 | 4 | 10 |
| 2003 | 11 | 6 |
| 2004 | 1 | 7 |
| 2005 | 4 | 8 |
| 2006 | 12 | 5 |
| 2007 | 3 | 7 |
| 2008 | 2 | 8 |
| 2009 | 0 | 2 |
| 2010 | 3 | 4 |
| 2011 | 4 | 3 |
| 2012 | 2 | 4 |
| 2013 | 6 | 3 |
| 2014 | 5 | 7 |
| 2015 | 5 | 4 |
| 2016 | 8 | 8 |
| 2017 | 4 | 2 |
| 2018 | 1 | 3 |
| 2019 | 3 | 2 |
| 2020 | 2 | 1 |
| 2021 | 1 | 0 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 1 | 2 |
| 2025 | 0 | 0 |
| 2026 | 1 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Synthetic methods of making (2H-1, 2, 3-triazol-2-yl) phenyl compounds as orexin receptor modulators10 Mar 2026US 12,570,658 B2Janssen Pharmaceutica NV
- Sphingosine kinase inhibitors23 Jan 2024US RE49,811 E1Apogee Biotechnology Corporation
- Autotaxin inhibitors21 Sep 2021US 11,124,490 B2The University of Memphis
- Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders24 Mar 2020US 10,597,381 B2The Trustees of Columbia University in the City of New York
- Bis-diazeniumdiolate compounds as anti-cancer agents11 Feb 2020US 10,556,875 B2Arizona Board of Regents on behalf of Arizona State University
- A method of treating seeds and seeds produced thereby13 Aug 2026US 2026/0231848 A1Cyprus University of Technology
- Novel inhibitors of dna damage responses for cancer therapy23 Jul 2026US 2026/0209193 A1The Regents of the University of California
- 2-((2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine25 Jun 2026US 2026/0176242 A1Axsome Therapeutics, Inc.
- Phenoxy-acetyl-thioureido-benzenesulfonamide derivatives, and their uses28 Nov 2024US 2024/0391872 A1Centre National De La Recherche Scientifique
- Bench-stable triazene compositions for protein modification22 Aug 2024US 2024/0277847 A1Arizona Board of Regents on Behalf of the University of Arizona
Most cited
By later US patents
- Lipids and compositions for intracellular delivery of biologically active compounds247US 8,691,750 B2Axolabs GmbH · 2014
- Methods for generating high titer helper-free preparations of released recombinant AAV vectors183US 6,566,118 B1Targeted Genetics Corporation · 2003
- Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs103US 5,366,997 AThe United States of America, as represented by the Secretary, Department of Health and Human Services · 1994
- Apoptosis promoters88US 7,767,684 B2Abbott Laboratories · 2010
- Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof75US 5,039,705 AThe United States of America as represented by the Department of Health and Human Services · 1991